Lux Health Tech Acquisition Corp. (NASDAQ:LUXA) announced this afternoon that it will not consummate a business combination and will instead dissolve and liquidate its trust, effective as of the close of business on October 29.
Lux Health Tech’s liquidation comes just a month after it had signed a non-binding letter of intent (LOI) to combine with an unnamed leading life sciences company. Little else was disclosed in that press release regarding the transaction, but the healthcare-focused SPAC expected to announce further information once the agreement was executed, which was expected to occur in the second half of 2022.
Following the close of business, public shares of LUXA will be deemed cancelled and will represent only the right to receive the redemption amount of $10.04. The SPAC raised $300 million in its October 2020 IPO and originally aimed to combine with a healthcare technology target with an experienced management team of serial entrepreneurs and acclaimed scientists.
As a result of the liquidation, Lux Health Tech has cancelled its special meeting for shareholders on October 13. The management team did not comment on the difficulties of its target search, but a handful of SPACs have recently noted that a challenging environment of high redemptions as well as a potential excise tax on redemptions have caused teams to liquidate.
Lux Health Tech is now the 33rd SPAC to announce its intention to liquidate in 2022.
With the passage this weekend of $95 billion in funding for Ukraine, Israel and Taiwan by the House of Representatives, some focus has gone back towards the defense sector, which has generally had a good year as a whole. But, SPACs have not been as active in defense, despite the fact that companies in the...
At the SPAC of Dawn As April’s sleepy month for SPAC news continues, there is only one special meeting on the docket to consider a SPAC deal approval, that being today’s vote on Pegasus Digital Mobility‘s (NYSE:PGSS) combination with equipment manufacturer Schmid. Three more SPACs are facing extension votes this week, including Pyrophyte (NYSE:PHYT), whose...
Terms Tracker for the Week Ending April 19, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Passover and school spring break starts next week, which most likely means a slowdown in SPAC filing activity. Although Churchill IX is now rumored to...
Despite a week of general pull-backs in the market, fintech firm Ibotta (NYSE:IBTA) nonetheless took the dive and had a good week debuting via a traditional IPO in the choppy waters. The company, which provides app-based consumer cashback discounts on purchases, priced its IPO at $88, above its proposed range of $76 to $84, and...
At the SPAC of Dawn Happy Friday! SPACInsider has unveiled new presets on SPAC Performance accessible via the Data drop-down to easily sort for the highest and lowest performing active SPACs and de-SPACs. On the de-SPAC side, Vertiv (NYSE:VRT) continues to be well ahead of the pack, logging a 710% return by share price adjusted...